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Background: Genome-wide methylation arrays are increasingly used tools in studies of complex medical disorders.
Because of their expense and potential utility to the scientific community, current federal policy dictates that data
from these arrays, like those from genome-wide genotyping arrays, be deposited in publicly available databases.
Unlike the genotyping information, access to the expression data is not restricted. An underlying supposition in
the current nonrestricted access to methylation data is the belief that protected health and personal identifying
information cannot be simultaneously extracted from these arrays.
Results: In this communication, we analyze methylation data from the Illumina HumanMethylation450 array and
show that genotype at 1,069 highly informative loci, and both alcohol and smoking consumption information, can
be derived from the array data.
Conclusions: We conclude that both potentially personally identifying information and substance-use histories can
be simultaneously derived from methylation array data. Because access to genetic information about a database
subject or one of their relatives is critical to the de-identification process, this risk of de-identification is limited at
the current time. We propose that access to genome-wide methylation data be restricted to institutionally approved
investigators who accede to data use agreements prohibiting re-identification.
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The balance between the right to privacy and the public
interest in advancing medical science is a dynamic rela-
tionship. This is particularly true for studies of complex
medical disorders. Over the past decade, vast databases
of biological information, both private and governmental,
have been established. A major factor in their rapid
growth has been policies mandating the deposition of all
genome-wide array data in publicly available repositories,
such as those administered by the National Center for
Biotechnology Information (NCBI) [1].
Without a doubt, these policies have led to significant
advances in many areas including evolutionary biology and
healthcare. With respect to medical illness, repositories* Correspondence: robert-philibert@uiowa.edu
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unless otherwise stated.of genome-wide genetic data are routinely utilized in
meta-analyses of cardiopulmonary, endocrinological
and mental health disorders. An underlying supposition
in making genome-wide genetic data publicly available
is the belief that the information contained within them
cannot be used to both infer disease status and uniquely
identify individuals. The rationale for the first assumption
rests on a firm foundation of medical evidence which
shows that for the vast majority of non-autosomal domin-
ant disorders, genetic information alone cannot be used to
absolutely determine whether a given individual actually
has a medical disorder. For the more common complex
disorders, this is undoubtedly true. For example, with
respect to Type 2 Diabetes (T2DM), which is perhaps
the best understood common complex medical disorder
from a genetic point of view, individual genotyping data
is of relatively little value in determining whether a
given individual is at risk, let alone currently ill [2,3].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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erroneous expectation that anonymized genome-wide
genetic data contained within repositories could not be
linked to identifiable individuals.
Recent developments in bioinformatics have shown
clearly that the assumption that genotype data in public
repositories cannot be tied to identifiable individuals is
not correct in all cases. For example, Gymek and col-
leagues reported a method to triangulate the identity of
a sample donor using genomic data and surnames from
publicly available databases [4]. This development, in
combination with other isolated but related issues, such
as the sequencing of the commonly used HeLa cell line,
which unintentionally allowed the conveyance of the
likely genetic vulnerabilities of close relatives of Henrietta
Lacks, have led to changes in the way genome-wide gen-
etic information is handled [5]. However, the severity of
these concerns has been tempered by the fact that, with
the exception of isolated instances, protected information
regarding diseases status has not been compromised. That
is, the ability of genome-wide data to both uniquely
identify an individual and infer disease status is relatively
limited. Nevertheless, as a precaution, access to full
genetic information is restricted [6].
In contrast, the deposition of genome-wide methylation
data, such as that of the Illumina HumanGenome450
BeadArray to the Gene Omnibus Expression (GEO)
repository has largely escaped scrutiny [7]. The ration-
ale for this relative lack of concern is the unwritten
supposition that methylation data cannot be used to
uniquely identify individuals or convey sensitive protected
health information.
Unfortunately, emerging data indicate that both of these
assumptions may be incorrect. Recently, our consortium
has demonstrated that consumption histories of both
tobacco and alcohol can be accurately inferred from the
DNA methylation signature of peripheral white blood cells
[8-11]. In this communication, we describe a method by
which information from a DNA methylation array could
be used to generate individually identifying genetic profiles
and also to infer the substance-use consumption of study
participants. We then discuss the potential for the misuse
of this data by those with access to genetic information of
the study participants or their close relatives.
Results
The suitability of Illumina array DNA methylation data
for use in genotyping was explored in two ways. As a
first approximation of the total variation, the beta values
for all 21,969 probes mapping to chromosome 16 were
plotted and visually inspected for possible genetic influ-
ences on methylation. Overall, 707 probes displayed a
tri-modal distribution roughly consistent with an additive
effect of genotype on DNA methylation.In the more exacting second approach to inferring
genotype, we attempted to build on the prior observations
by Shoemaker and colleagues who noted nearly com-
plete, stoichiometric losses of the methylation signal in
response to cytosine polymorphisms in heavily methyl-
ated (approximately 95 to 100%) CpG residues, [12] by
identifying those sites with ideal beta value distributions
for genotyping inference (that is, 100%, 50% or 0% methy-
lation). First, the cleaned beta values for all 485,577 loci
interrogated by the Illumina HumanMethylation450 array
in our recent study of the effects of smoking on DNA
methylation in a cohort of 111 African American females
were binned into three groups, X, Y and Z (X >0.7, 0.7 < Y
<0.3, Z <0.25), which potentially represent the genotypes
CC, CD, or DD where ‘D’ represents an A, G or T, at the
putative cytosine position of the CpG dinucleotide pair,
respectfully [13]. A total of 1,383 probes with at least 106
(95%) of the values mapping to those bins and having
at least four observations in both Bin X and Bin Z were
identified. The binning values were converted to geno-
types and then analyzed for minor allele frequency and
compliance with the Hardy Weinberg Equilibrium (HWE).
A total of 1,069 had HWE P values >0.01, with their minor
allele frequencies ranging from 0.105 to 0.5. A listing of
the 30 most informative loci is given in Table 1, and a
complete listing of all 1,069 probes, including probe
sequence information is given in Additional file 1: Table S1.
Histograms of the beta value distribution at 30 most
informative loci are given in Additional file 2: Figure S1.
Using the sequence information contained in the Illu-
mina probe annotation files and the sequence alignment
algorithm of the University of California, Santa Clara
(UCSC) Genome Browser, we mapped the CpG residue
targeted by each of the probes back to the genome to
determine whether or not the position occupied by the
cytosine nucleotide was known to be polymorphic. In 29 of
the top 30 cases, the position of the CpG residue targeted
by the probe was the site of a known highly informative C
to T transition polymorphism whose USCS Genome
Browser-listed heterozygosity closely matched that ob-
served in our study. The sole exception in that group of
30 was with respect to cg19214707, which instead con-
tained several polymorphisms within the probe binding
site. A review of a random sampling of the rest 1,069
probes listed in Additional file 1: Table S1 showed a high
correlation between the heterozygosity observed in our
sample of 111 subjects and that reported on the UCSC
genome browser.
To formally determine whether allele binning of methy-
lation signal corresponded to actual genotypes, we geno-
typed 12 random Family and Community Health Studies
(FACHS) subjects at two of the loci (cg10695549 and
cg21028319) using conventional MspI restriction endo-
nuclease digestion. The results from each of the agarose
Table 1 Location and heterozygosity of the top thirty
Illumina probes
Illumina ID CHR Position (bp)1 Observed
heterozygosity
UCSC2
heterozygosity
cg11036359 6 29759078 0.55 0.45
cg03115532 6 28185726 0.46 0.43
cg10695549 8 18432000 0.53 0.50
cg22309983 17 3497580 0.53 0.31
cg09533869 8 97747124 0.48 0.45
cg13078798 1 92203667 0.41 0.46
cg23603995 6 157198648 0.54 0.41
cg27467876 8 22266134 0.50 0.50
cg27625131 13 113105794 0.58 0.21
cg26690318 10 100167465 0.56 0.46
cg16999994 11 1001560 0.56 0.50
cg27056740 14 101507727 0.56 0.49
cg18816122 5 164064 0.45 0.50
cg13821051 2 101124858 0.52 0.46
cg06688803 19 45457306 0.46 0.49
cg18662228 2 236867804 0.52 0.50
cg27076160 10 64431533 0.62 0.30
cg22953237 7 31425682 0.44 0.02
cg16814680 8 91681699 0.44 0.50
cg18239511 14 96563269 0.55 0.39
cg13379757 10 22717154 0.46 0.30
cg19214707 7 3157722 0.48 0.19
cg11019791 22 48896579 0.48 0.45
cg04506342 2 160463692 0.51 0.48
cg25046571 6 29794657 0.51 0.50
cg10117599 7 624424 0.51 0.48
cg16398051 15 100821466 0.51 0.50
cg18514595 22 49579968 0.51 0.49
cg16675926 1 233518998 0.50 0.49
cg02299007 8 1140574 0.46 0.48
1Position of CpG residue according to Genome Build 37.
2Heterozygosity as reported by UCSC Genome Browser.
Figure 1 The relationship between DNA methylation at
cg05575921 and self-reported Smoking Status.
Philibert et al. Clinical Epigenetics 2014, 6:28 Page 3 of 6
http://www.clinicalepigeneticsjournal.com/content/6/1/28gel based assessments showed complete correspondence
to that imputed from the arrays.
As a demonstration of the usefulness of these arrays
to assess substance-use consumption status for those
unfamiliar, we repeated our previously published ana-
lysis of the relationship of methylation at cg05575921
to self-reported smoking status in these 111 individuals.
We and others have shown that assessment of methyla-
tion status at cg05575921, which targets a CpG residue
in the aryl hydrocarbon receptor repressor, can be used
to assess smoking history [8-11,13-18]. Figure 1 illustrates
the relationship between smoking status and DNAmethylation at cg05575921. As the figure demonstrates,
methylation status at this residue is highly correlated with
self-reported smoking status.
Discussion
The frequent use of information from public databases in
many of the most highly cited scientific papers highlights
the value of these repositories. Nevertheless, recent
advances in our ability to infer information about the hu-
man subject participants who contributed to those studies
raises concerns for potential abuse of that information.
At the current time, the capability to link the disease
status information contained within these arrays to indi-
viduals is relatively limited. However, as the current exer-
cise demonstrates, this is not due to the lack of potential
genetic markers in the Illumina array. Our rudimentary
analysis that focused on identifying highly informative
loci that were fully methylated, half methylated or fully
demethylated as a function of genetic variation at or
near the CpG site, generated over 1,000 informative
loci. However, this is likely a gross underestimate of the
number of informative loci. Our manual survey of
chromosome 16 shows that if the stringency was relaxed
to include those sites that were normally not fully methyl-
ated or were less informative than those in Table 1, the
number of potential loci of that could be used to infer
genotype would markedly increase. Indeed, Shoemaker
noted over 200,000 annotated SNPs that map to CpG sites
[12]. Hence, it is highly likely many more genetically
informative probes could be identified if more advanced
methods were use to ‘bin’ alleles.
Because a relatively small set of loci can be used to
match one genetic sample to another, it should be possible
using the thousand or so markers that we have already
identified, to develop a robust, unique, genetic profile of
any anonymous genome-wide methylation array donor.
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person, one would need either a genetic sample of the
individual to match, or else one would need to know that
a given individual participated in a methylation study and
have genetic information from a close relative, such as a
sibling or first cousin. In our opinion, this is not a likely
possibility at the current time. The GEO database only list
3,559 arrays of human peripheral blood methylation. Still,
given the rapid growth of this database, on-line genetic
information and the bitterness sometimes seen in divorce
proceedings or other situations in which considerable
sums of money or prestige are involved, it is not incon-
ceivable that this could happen in the future. Furthermore,
if our ability to identify individuals in open access genetic
databases accelerates or if individuals begin to make
non-anonymized genomes more common, the ability to
identify those who have contributed to genome-wide
methylation studies will become correspondingly easier.
Not everyone who has contributed to these databases
needs to be alarmed. Although the current status of a
number of medical disorders can be imputed from these
arrays is growing, [19,20] it is the recent demonstrations
that these methylation arrays can be used to infer
substance-use histories that may cause the greatest con-
cerns. With respect to mental health information, only
tobacco and alcohol consumption information can be
accurately gleaned from these arrays at the current time
[9,21]. However, it is highly likely that our ability to assess
other substance consumption, such as that of cannabis
use, or other mental health status will be developed in the
near future.
Currently, the identities of the donors of these data
are not protected from discovery. Protection under the
Healthcare Improvement and Portability Act (HIPAA)
Privacy rule only applies to protected health information
held by covered entities such as health care institutions
[22]. However, to be protected the information must be
‘individually identifiable.’ HIPAA does not generally
protect data held in publicly available repositories because
the Privacy rule generally does not apply to de-identified
health information [23]. The current demonstration that
extensive genotype and substance-use profiles can be ex-
tracted from these arrays challenges this de-identification
hypothesis and calls into question the lack of privacy
protection.
The risk of re-identification is well known and should
not take precedence over the rights of individual research
subjects [24]. In 2010, Benitez and Malin quantified
substantial differential risks of re-identification based on
state-by-state variations in voter registries (their chosen
triangulation datasets) [25]. The narrower question of
potentially identifying genetic information has been the
subject of several proposals for regulatory reform. For
example, in 2009 an Institute of Medicine committeeadvocated ‘a focus on strong security measures and the
adoption of strict prohibitions and legal sanctions against
the unauthorized re-identification of individuals from DNA
sequences.’ [26]. In 2012, the Presidential Commission for
the Study of Bioethical Issues called for more consistent
privacy baseline rules and a focus on data security [27].
Neither report resulted in regulatory reform.
There are several potential solutions to the re-
identification risks posed by methylation data. One of
them is to require data use agreements and to restrict
access of array or similarly informative data to those
investigators appropriately vetted by their institutions.
There are many examples of data use prohibitions on
re-identification, such as the National Practitioner Data
Bank’s conditions for the use of its Public Use Data File
[28]. Another would be to remove the data for the most
genetically informative markers from the database. Though
the two approaches are not mutually exclusive, vetting of
applicants might be the preferred mechanism. Institutional
Review Boards are already available to the vast majority
of researchers who would seek this type of data. It is
also possible to implement the second mechanism as well.
However, if this mechanism is to be completely effective
ethnically inclusive examinations to determine which data
should be removed must be undertaken.
Conclusions
In summary, we report that both highly informative genetic
profiles and substance-use histories can be developed from
the same Illumina HumanGenome450 arrays. We suggest
that policy changes be initiated to address potential loss of
confidentiality.
Availability of supporting data
The methylation data used in this study are freely avail-
able via the Gene Expression Omnibus repository [GEO
Accession: GSE53045]. A listing of all 1069 polymorphic
sites discussed in this manuscript is contained in the
Additional files.
Methods
The DNA methylation information contained in this
study was derived and deposited as part of the study
plan for the National Institutes for Health (NIH)-funded
study ‘The Effects of Smoking on DNA Methylation in
Primary Human Lymphocytes’ (R21DA034457, [GEO
Accession: GSE53045]). All procedures and protocols
in that study were approved by the University of Iowa
Institutional Review Board. Self-reported smoking data
on the 111 female subjects was obtained using an
adapted version of the Semi-Structured Assessment for
the Genetics of Alcoholism, Version II [29]. Biomaterial
for the methylation analyses was obtained via phlebot-
omy at the time of the interview.
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assessments of peripheral mononuclear cell DNA of
111 African-American females using the Illumina Human-
Methylation450 BeadChip (Illumina, San Diego, CA,
USA), which contains 485,577 probes recognizing at least
20,216 transcripts, potential transcripts or CpG islands.
The procedures and protocols used in the preparation of
the DNA and cleaning of the data have been described in
detail previously [13].
Binning of beta values was conducted using Excel
(Microsoft, Redmond, WA, USA). Plotting of data values
was accomplished using JMP Version 11 (SAS, Cary, SC,
USA).
Genotyping at cg10695549 and cg21028319 was
conducted using a standard restriction enzyme digest
approach. In brief, we searched the key sequence infor-
mation provided in the probe annotation files of the 50
most informative loci to identify those with CpG sites
that could be potentially recognized by the restriction
enzyme MspI (which cuts at CCGG tetramers). Primers
flanking each CpG site at two of these sites, F- GCT
GTAATTATACATCCAGCTATGG and R- TTTTTGTT
TCCCTTCTGAGC for cg10695549; and F- TTGCAAA
CGATGAGAACTGAG and R- CGTTTACCAGCCCAT
GCTA for cg21028319; were used to amplify the locus
using DNA from 12 random FACHS subjects. Aliquots of
the resulting PCR products were then digested using 3 u
of MspI under the conditions suggested by the manufac-
turer (New England Biolabs, Ipswich, MA, USA). The
resulting products were then electrophoresed on standard
2% agarose gel and the resulting genotypes called by
personnel blinded to methylation allele status.
Additional files
Additional file 1: Table S1. A listing of 1069 Genetically Informative
Methylation Probes.
Additional file 2: Figure S1. Binning histograms for the 50 genetically
most informative probes.
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